Who We Are

Who We Are

Egetis is a global rare disease company dedicated to improving and extending the lives of people affected by rare diseases.

We focus on serious conditions with high unmet medical need, where scientific understanding and targeted development can create meaningful opportunities for patients. We work closely with patients, caregivers, clinicians and partners to ensure our development reflects real-world needs.

Our team brings together deep rare disease expertise and a shared commitment to addressing the challenges patients face. This combination of expertise and purpose enables us to take a thoughtful and focused approach to development, from early scientific insight to patient access. This enables us to advance therapies through regulatory approval and support access globally.

Everything we do is guided by a simple principle: to care for the rare by turning scientific progress into meaningful impact for patients and families.

The development of Emcitate® (tiratricol) builds on decades of scientific research into thyroid hormone biology, including pioneering work conducted at Erasmus MC and other academic institutions that advanced the understanding of MCT8 deficiency.